-4%
Zoledronic Acid is a potent bisphosphonate that inhibits osteoclast-mediated bone resorption. Its action is due to a strong affinity for mineralized bone, particularly at sites of high turnover. The primary molecular target is farnesyl pyrophosphate synthase in osteoclasts, leading to reduced bone breakdown. Its long duration of effect is attributed to strong binding with bone mineral.
Zoldix is prescribed for:
- Treatment and prevention of postmenopausal osteoporosis
- Increasing bone mass in men with osteoporosis
- Management and prevention of glucocorticoid-induced osteoporosis
- Treatment of Paget’s disease of bone in both men and women
Limitations of use: The optimal duration of therapy is not clearly established. For patients at low fracture risk, discontinuation should be considered after 3–5 years of use.
- Pediatric: Not indicated.
- Geriatric: Monitor renal function closely.
- Renal impairment: Contraindicated if CrCl <35 mL/min.
- Hepatic impairment: No adjustment needed (not metabolized hepatically).
- Pregnancy & Lactation: Contraindicated – may cause fetal harm and not recommended during breastfeeding.